Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 November 2021
Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant (IPG695)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 May 2021
Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 February 2018
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)Product type:GuidanceProgramme:Clinical guidelineLast updated: 23 May 2017Published: 12 June 2013
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC